Raltegravir pharmacokinetics during pregnancy. - Wikidata - wikimedia - TriplyDB

Raltegravir pharmacokinetics during pregnancy.

Raltegravir pharmacokinetics during pregnancy.

http://www.wikidata.org/entity/Q34422111

about

Pregnancy-Associated Changes in Pharmacokinetics: A Systematic Review Antiretroviral Therapy Containing Raltegravir to Prevent Mother-to-Child Transmission of HIV in Infected Pregnant Women A case series of third-trimester raltegravir initiation: Impact on maternal HIV-1 viral load and obstetrical outcomes Bidirectional Transfer of Raltegravir in an Ex Vivo Human Cotyledon Perfusion Model.Integrase inhibitors in late pregnancy and rapid HIV viral load reduction.Pharmacokinetic and pharmacodynamic evaluation of raltegravir and experience from clinical trials in HIV-positive patients.Toward a universal antiretroviral regimen: special considerations of pregnancy and breast feeding.Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors.Pharmacokinetics and Placental Transfer of Elvitegravir, Dolutegravir, and Other Antiretrovirals during Pregnancy.Advancing HIV research with pregnant women: navigating challenges and opportunities.HIV viraemia and mother-to-child transmission risk after antiretroviral therapy initiation in pregnancy in Cape Town, South Africa.A Single-Center Retrospective Cohort Analysis of Maternal and Infant Outcomes in HIV-Infected Mothers Treated with Integrase Inhibitors During Pregnancy.Raltegravir in HIV-1-Infected Pregnant Women: Pharmacokinetics, Safety, and Efficacy.Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV.

P2860

Q28109657-1E1ADFFD-0CD8-47C8-BB61-E52B1E40F3A4 Q33815637-8B7E05F3-1DA6-4DF2-9B61-782B94824B2B Q35867233-D08ABB7F-7F57-4969-BC02-A5ED07D10D51 Q36887876-CAFD069E-0A1F-400E-8BDE-5AFCCFC165D9 Q37199763-B7BC6BC0-6768-4392-9C2A-9CA03592F187 Q38527537-2FEC2D89-E578-4526-A282-E5E5C2C42336 Q38828635-AF3B31DB-6BC2-4763-9274-1EBA904892D9 Q38868949-9E973701-3797-46F2-B053-1E2F2FBCCE96 Q38872808-769F1758-36DE-4034-9DFC-A43C9BB25597 Q39525139-94B29C7B-DB8D-4D6F-A1F4-665410382CFA Q39648148-1B0B4898-0F81-4F56-845D-AFA741CC34B4 Q40041922-EB38DB0B-4156-479C-8850-54363BD8D7CC Q41257241-D04ABFA3-757B-4AAC-AFE7-2611751D744B Q47548999-8DB7CAD3-7633-4B5D-B3E6-81B611BF785D

P2860

Raltegravir pharmacokinetics during pregnancy.

http://www.wikidata.org/entity/Q34422111

description

2014 nî lūn-bûn

@nan

2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Raltegravir pharmacokinetics during pregnancy.

@ast

Raltegravir pharmacokinetics during pregnancy.

@en

Raltegravir pharmacokinetics during pregnancy.

@nl

type

label

Raltegravir pharmacokinetics during pregnancy.

@ast

Raltegravir pharmacokinetics during pregnancy.

@en

Raltegravir pharmacokinetics during pregnancy.

@nl

prefLabel

Raltegravir pharmacokinetics during pregnancy.

@ast

Raltegravir pharmacokinetics during pregnancy.

@en

Raltegravir pharmacokinetics during pregnancy.

@nl

P1433

Q34422111-FFD335EB-6CA7-4656-883E-5F4AA00570DE

P1476

Q34422111-FE6C9631-CD87-4C7B-AC76-F67F67D84919

P2093

Q34422111-0CA83D40-89AB-447A-843D-C699C393975E

Q34422111-1A8D8F9D-977F-48BF-875E-C3A075087079

Q34422111-39DC32AC-28D1-443F-812F-C0E3C95D37D4

Q34422111-43D464AE-92EF-463E-8B62-465D5B2C75B4

Q34422111-50C492CC-DE93-4424-9A66-ADB51265C00C

Q34422111-64136578-3EB5-49A2-A224-3020CF3525C3

Q34422111-8D735473-4097-4A70-A6C9-45E77FF7361B

Q34422111-8E4783C7-636D-4D71-A61B-6AE760D92EC8

Q34422111-92DCA6B9-31CE-4821-9359-743953492056

Q34422111-AA7454B6-3B9B-440C-BC79-4074686AAA7B

P2860

Q34422111-03C97B0E-980E-42F4-813B-44619E522635

Q34422111-0F16BCF3-DE94-4825-9C41-775AFF19F161

Q34422111-18C0FF90-B9E1-49F1-A144-F75D59AD7030

Q34422111-3104A398-5C67-4487-B1A7-E4CBB30E0A5C

Q34422111-5286CB4F-264E-4E5D-BDA1-C63B7885E6B0

Q34422111-61CBD6B8-8988-4B23-8626-3BA1BD879323

Q34422111-6709FDB9-C9E6-4D2C-8EDB-A80BB0F4A6F6

Q34422111-E3542E9D-0ADA-4F81-9DEC-22692587069E

Q34422111-E9354254-13D2-4544-9ED5-10C4DC807B22

Q34422111-E9D2D2E8-A299-437A-B5E9-F441F06D0FFD

P304

Q34422111-845FF8FA-17FD-4B72-8B69-DAB226D11529

P31

Q34422111-C8B04753-9BAF-43F5-8CFA-97BC61D7332A

P356

Q34422111-A4B01D62-0101-4385-9CF5-EC83223018BF

P407

Q34422111-64639107-5C97-43A5-847A-C4800C6EBCE8

P433

Q34422111-9A39AB32-B0CF-4A20-B57C-BBCC96462EB5

P478

Q34422111-24A14E7C-CC78-4B97-A9AC-23E75240F030

P50

Q34422111-BF4F8F96-88D2-4258-B993-66549831166C

Q34422111-E3436585-9E93-409E-B6F0-0596E5D5284B

P577

Q34422111-0F6F1620-ABE7-4397-B553-6958C42A1288

P698

Q34422111-A1EC6B64-6EAA-44A8-BDCD-39A3CAB6552F

P932

Q34422111-979480BD-2027-4E0F-8432-6BF746A9CE7B

P356

QAI.0000000000000318

P1433

Journal of Acquired Immune Deficiency Syndromes

P1476

Raltegravir pharmacokinetics during pregnancy.

@en

P2093

Alice Stek

http://www.w3.org/2001/XMLSchema#string

Brookie M Best

http://www.w3.org/2001/XMLSchema#string

D Heather Watts

http://www.w3.org/2001/XMLSchema#string

David E Shapiro

http://www.w3.org/2001/XMLSchema#string

Edmund V Capparelli

http://www.w3.org/2001/XMLSchema#string

Elizabeth Hawkins

http://www.w3.org/2001/XMLSchema#string

Francesca Aweeka

http://www.w3.org/2001/XMLSchema#string

IMPAACT 1026s study team

http://www.w3.org/2001/XMLSchema#string

Jiajia Wang

http://www.w3.org/2001/XMLSchema#string

Mark Mirochnick

http://www.w3.org/2001/XMLSchema#string

P2860

Raltegravir pharmacokinetics in treatment-naive patients is not influenced by race: results from the raltegravir early therapy in African-Americans living with HIV (REAL) study.

Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir.

Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248

Use of newer antiretroviral agents, darunavir and etravirine with or without raltegravir, in pregnancy: a report of two cases.

Increase in transaminase levels following the use of raltegravir in a woman with a high HIV viral load at 35 weeks of pregnancy.

Rapid decline in HIV viral load when introducing raltegravir-containing antiretroviral treatment late in pregnancy.

High neonatal concentrations of raltegravir following transplacental transfer in HIV-1 positive pregnant women.

Rapid HIV-RNA decline following addition of raltegravir and tenofovir to ongoing highly active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancy.

Reduced lopinavir exposure during pregnancy.

Atazanavir modestly increases plasma levels of raltegravir in healthy subjects.

P304

375-381

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/QAI.0000000000000318

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

67

http://www.w3.org/2001/XMLSchema#string

P50

Regis Kreitchmann

Elizabeth Smith

P577

2014-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25162818

http://www.w3.org/2001/XMLSchema#string

P932

4213295

http://www.w3.org/2001/XMLSchema#string